In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Resolve Therapeutics LLC

www.resolvebio.com

Latest From Resolve Therapeutics LLC

Declaration Of Independence: Perlstein Lab Goes Solo Against Rare Diseases

Unable to land an academic job and unwilling to work in industry, Ethan Perlstein is using 21st-century tools to bootstrap his rare-disease drug discovery platform. But can he raise a million dollars?

BioPharmaceutical United States

Declaration Of Independence: Perlstein Lab Goes Solo Against Rare Diseases

Unable to land an academic job and unwilling to work in industry, Ethan Perlstein is using 21st-century tools to bootstrap his rare-disease drug discovery platform. But can he raise a million dollars?

BioPharmaceutical United States

Start-Up Quarterly Statistics, Q1 2013

Start-up company fundraising got off to a slow start in 2013: life sciences companies brought in $398.7 million, roughly 59% less than in the final quarter of 2012. Of the total raised, 84% went to biopharmas. The majority of start-up alliances were for discovery- or preclinical-stage products and there were four start-up acquisitions for the quarter – three in biopharma and one in the medical device sector.

BioPharmaceutical Medical Device

Deals In Depth: February 2013

Biogen paid over $3 billion to buy out Elan’s share of Tysabri. Mylan and Cardinal Health made two billion-dollar-plus acquisitions. FOPOs represented over 50% of the $827 million in biopharma financing. The $322 million in device fundraising was dominated by late-stage venture rounds.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Resolve Therapeutics LLC
  • Senior Management
  • James Posada, PhD, CEO
    Chris Gabel, PhD, CSO
  • Contact Info
  • Resolve Therapeutics LLC
    Phone: (208) 727-7010
    454 North 34th St.
    Seattle, WA 98103
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register